What type of study is this?

September 10, 2025Annals of HematologyOpen Access

Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients

View Full Paper

Ask AI

Bookmark

Authors

Analysis shows no survival benefit of idarubicin with cytarabine in AML, highlighting infection risks.

The combination of idarubicin and high-dose cytarabine did not improve long-term survival in AML patients.
Patients receiving idarubicin required a longer recovery period from agranulocytosis during hospitalization.
Infections were more frequent among patients treated with idarubicin compared to those receiving cytarabine alone.
The study included 102 patients who achieved complete response and underwent consolidation therapy.

Qian et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark